[USA] Solazyme is a renewable oil and bioproducts company that transforms a range of low-cost plant-based sugars into high-value oils. Headquartered in South San Francisco, Solazyme’s renewable products can replace or enhance oils derived from the world’s three existing sources – petroleum, plants and animal fats.
Initially, Solazyme is focused on commercializing its products into three target markets: (1) fuels and chemicals, (2) nutrition and (3) skin and personal care.
Bottom line, the Digest noted, “Moema’s delayed, the big volumes are now in 2016 or 2017, so Solazyme’s shifting to higher margin, lower-volume markets.”
The stock went into free-fall after this late-year shift, even after a signature partnership with Versalis was announced to commercialize Encapso drilling oils. Versalis said that its initial emphasis for Encapso will be oil and gas fields operated by its parent company Eni, which represent a significant amount of the world’s petroleum drilling activity. Encapso will be featured as part of the company’s recently launched Specialty Oilfield Chemicals product portfolio.
Those are timing issues for investors — and legitimate for their purposes, of course. But let’s focus on the larger story here — while significant ramp-up risk is out there for the long-term, investors have priced in almost zero revenue growth next year, at this stock price, if we take the Cowen & Company analysis which pegged a $4 target price to 15% growth. Which makes this an opportunity for those who see in the Eni deal the means of revenue growth that investors have discounted for the near-term.
View original article at: Transformative algae products at scale: The Digest’s 2015 8-Slide Guide to Solazyme